Is berberine HCl (hydrochloride) from Berberis vulgaris extract safe for individuals with G6PD (Glucose-6-phosphate dehydrogenase) deficiency?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 14, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Berberine Safety in G6PD Deficiency

Berberine HCl from Berberis vulgaris can likely be used safely in individuals with G6PD deficiency, as there is no documented evidence linking berberine to hemolysis in G6PD-deficient patients.

Evidence-Based Assessment

The available evidence does not identify berberine as a contraindicated medication in G6PD deficiency. A comprehensive systematic review of herbal and dietary supplements in G6PD deficiency found insufficient evidence to contravene the use of most herbal products at therapeutic doses, with only henna showing a clear link to hemolysis 1. Berberine was not among the substances identified as problematic 1.

Established High-Risk Medications to Avoid

For context, only seven medications have solid evidence for prohibition in G6PD deficiency 2:

  • Dapsone 3, 4
  • Methylene blue (methylthioninium chloride) 3, 4
  • Nitrofurantoin 2
  • Phenazopyridine 2
  • Primaquine 4, 2
  • Rasburicase 3, 2
  • Tolonium chloride (toluidine blue) 2

Clinical Monitoring Approach

Despite the lack of evidence for harm, prudent monitoring is warranted when starting berberine in G6PD-deficient patients, particularly those with Mediterranean or Southeast Asian variants who experience more severe hemolytic reactions 4, 5.

Monitor for signs of hemolysis 3, 5:

  • Jaundice
  • Dark urine
  • Fatigue
  • Pallor

Important Caveats

The severity of G6PD deficiency varies significantly by genetic variant, with Mediterranean variants (Gdmed) causing more severe reactions than African variants (GdA-) 4, 5. Patients with Mediterranean variants may experience life-threatening hemolysis from oxidant drugs, while those with African variants typically have milder, self-limited episodes 4.

If any signs of hemolysis develop, immediately discontinue berberine and reassess the patient 3.

References

Guideline

Medication Safety in G6PD Deficiency

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Medications Contraindicated in G6PD Deficiency

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Safety of Oxi-nase Spray in G6PD Deficiency and Mild Thalassemia

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.